Butrans Patch Safety After Cardiac Stent Placement

Key Safety Considerations

• The European Society of Cardiology recommends that all patients with cardiac stents must continue their dual antiplatelet therapy (DAPT) without interruption while using the Butrans patch, with aspirin 75-100 mg daily plus clopidogrel 75 mg daily required for up to 6 months as the default antithrombotic strategy 3
• The American Heart Association suggests that buprenorphine does not interfere with guideline-directed coronary artery disease therapies, including aspirin, P2Y12 inhibitors, beta-blockers, ACE inhibitors/ARBs, and statins, and does not require dose adjustment or discontinuation of these antiplatelet agents 1
• The European Heart Society states that opioids like buprenorphine do not increase thrombotic risk, unlike NSAIDs, which should be avoided in patients with cardiac stents due to increased cardiovascular risk 2

Critical Antiplatelet Therapy Continuation

• The European Society of Cardiology recommends that following the initial DAPT period, lifelong aspirin therapy at 75-100 mg daily is mandatory 3, 2

Medication Interactions and Monitoring

• The American College of Cardiology suggests that no specific drug-drug interactions exist between buprenorphine and standard post-stent medications, and all cardiovascular medications should be continued without modification when initiating Butrans 1

Dosing Considerations

• The National Kidney Foundation recommends that dose adjustment is only necessary if creatinine clearance falls below 20 mL/min/1.73 m² 1
• The Mayo Clinic suggests that the transdermal formulation provides steady-state analgesia without requiring an opioid-free withdrawal period, and the patch avoids the need for frequent dosing that could complicate medication adherence in polypharmacy patients 4

Common Pitfalls to Avoid

• The European Heart Society warns that NSAIDs should be avoided as an alternative pain management strategy, as these significantly increase cardiovascular risk in stent patients 2
• The American Heart Association advises that antiplatelet therapy should not be discontinued to start pain management, as there is no need to modify DAPT when using buprenorphine 3, 2